Clinical trial · Interventional
Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer
Identifying the miR Fingerprint in NAF, Serum, and Tissue in Patients With Ductal Carcinoma in Situ (DCIS) or Invasive Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Could not identify collaborator and secure additional funding after transferring the record to Montefiore Medical Center
Summary
Brief summary (as posted)
The purpose of this study is to examine the genetic material called microRNA of three types of specimens from women with breast cancer. The study also seeks to examine the effectiveness of using a new agent called oxytocin to increase the amount of nipple fluid that can be collected during surgery.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Ductal Carcinoma in Situ | Breast Ductal Carcinoma In Situ | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intranasal Oxytocin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Oxytocin
- description
- Subjects would receive 4 IU of intranasal oxytocin; one spray in each nostril, single-use.
- interventionNames
- Drug: Intranasal Oxytocin
Primary outcomes (1)
- measure
- Percentage of Patients With Detection of microRNA in NAF, Serum, or Tissue
- timeFrame
- 3 years
Secondary outcomes (1)
- measure
- Percentage of Patients With Collection of ≥ 5 μL of Nipple Aspirate Fluid
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of Ductal carcinoma in situ (DCIS) or invasive breast cancer * Candidate for breast conserving surgery or mastectomy Exclusion Criteria: * Pregnant women * Prior Breast Cancer diagnosis * Adverse reaction to Oxytocin in the past
References
Publications (0)
Data not yet available